THE European Medicines Agency has extended its review of impurities in valsartan medicines, after discovering very low levels of N-nitrosodiethylamine (NDEA) in another active substance, losartan, made by India's Hetero Labs.
The precautionary review will now include losartan, olmesartan, candesartan and irbesartan.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Sep 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Sep 18
